225 related articles for article (PubMed ID: 21205755)
1. Congestive heart failure risk in patients with breast cancer treated with bevacizumab.
Choueiri TK; Mayer EL; Je Y; Rosenberg JE; Nguyen PL; Azzi GR; Bellmunt J; Burstein HJ; Schutz FA
J Clin Oncol; 2011 Feb; 29(6):632-8. PubMed ID: 21205755
[TBL] [Abstract][Full Text] [Related]
2. Risk of Congestive Heart Failure in Early Breast Cancer Patients Undergoing Adjuvant Treatment With Trastuzumab: A Meta-Analysis.
Long HD; Lin YE; Zhang JJ; Zhong WZ; Zheng RN
Oncologist; 2016 May; 21(5):547-54. PubMed ID: 27026675
[TBL] [Abstract][Full Text] [Related]
3. Integrating bevacizumab into the treatment of patients with early-stage breast cancer: focus on cardiac safety.
Yardley DA
Clin Breast Cancer; 2010 Apr; 10(2):119-29. PubMed ID: 20353933
[TBL] [Abstract][Full Text] [Related]
4. Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis.
Sher A; Wu S
Acta Oncol; 2011 Oct; 50(7):997-1005. PubMed ID: 21554028
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups.
Qi WX; Fu S; Zhang Q; Guo XM
Clin Drug Investig; 2014 Oct; 34(10):681-90. PubMed ID: 25096848
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side?
Verma N; Swain SM
J Clin Oncol; 2011 Feb; 29(6):603-6. PubMed ID: 21205751
[No Abstract] [Full Text] [Related]
7. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials.
Bria E; Cuppone F; Fornier M; Nisticò C; Carlini P; Milella M; Sperduti I; Terzoli E; Cognetti F; Giannarelli D
Breast Cancer Res Treat; 2008 May; 109(2):231-9. PubMed ID: 17638068
[TBL] [Abstract][Full Text] [Related]
8. Haematologic toxicities associated with the addition of bevacizumab in cancer patients.
Schutz FA; Jardim DL; Je Y; Choueiri TK
Eur J Cancer; 2011 May; 47(8):1161-74. PubMed ID: 21470847
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.
Richards CJ; Je Y; Schutz FA; Heng DY; Dallabrida SM; Moslehi JJ; Choueiri TK
J Clin Oncol; 2011 Sep; 29(25):3450-6. PubMed ID: 21810682
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
[TBL] [Abstract][Full Text] [Related]
12. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials.
Schutz FA; Je Y; Choueiri TK
Crit Rev Oncol Hematol; 2011 Nov; 80(2):291-300. PubMed ID: 21339073
[TBL] [Abstract][Full Text] [Related]
13. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Scappaticci FA; Skillings JR; Holden SN; Gerber HP; Miller K; Kabbinavar F; Bergsland E; Ngai J; Holmgren E; Wang J; Hurwitz H
J Natl Cancer Inst; 2007 Aug; 99(16):1232-9. PubMed ID: 17686822
[TBL] [Abstract][Full Text] [Related]
14. Clinical cardiac tolerability of trastuzumab.
Perez EA; Rodeheffer R
J Clin Oncol; 2004 Jan; 22(2):322-9. PubMed ID: 14722042
[TBL] [Abstract][Full Text] [Related]
15. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis.
Chen T; Xu T; Li Y; Liang C; Chen J; Lu Y; Wu Z; Wu S
Cancer Treat Rev; 2011 Jun; 37(4):312-20. PubMed ID: 20952131
[TBL] [Abstract][Full Text] [Related]
16. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
Pinder MC; Duan Z; Goodwin JS; Hortobagyi GN; Giordano SH
J Clin Oncol; 2007 Sep; 25(25):3808-15. PubMed ID: 17664460
[TBL] [Abstract][Full Text] [Related]
17. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.
Bengala C; Zamagni C; Pedrazzoli P; Matteucci P; Ballestrero A; Da Prada G; Martino M; Rosti G; Danova M; Bregni M; Jovic G; Guarneri V; Maur M; Conte PF;
Br J Cancer; 2006 Apr; 94(7):1016-20. PubMed ID: 16570045
[TBL] [Abstract][Full Text] [Related]
18. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.
Tassinari D; Sartori S; Papi M; Drudi F; Castellani C; Carloni F; Tombesi P; Lazzari-Agli L
Oncology; 2011; 80(5-6):350-8. PubMed ID: 21791945
[TBL] [Abstract][Full Text] [Related]
20. Risk profile of bevacizumab in patients with non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Cao C; Wang J; Bunjhoo H; Xu Y; Fang H
Acta Oncol; 2012 Feb; 51(2):151-6. PubMed ID: 22085338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
